

**FORM AOC - 1**  
**PURSUANT TO FIRST PROVISIO TO SUB-SECTION (3) OF SECTION 129 READ WITH THE RULE 5 OF COMPANIES (ACCOUNTS) RULES, 2014**  
**STATEMENT CONTAINING SALIENT FEATURES OF THE FINANCIAL STATEMENT OF SUBSIDIARIES / ASSOCIATE COMPANIES/ JOINT VENTURES**

Sr No	Name of the Subsidiary Company	Reporting Currency	Rate	Capital	Reserve	Part "A": Subsidiaries		Investment other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation	Provision for after Taxation	Profit / (Loss) after Taxation	Proposed Dividend	% of shareholding
						Total Assets	Total Liabilities							
1	Green Eco Development Centre Ltd.	INR	1.00	1.0	(4.8)	0.6	4.4	-	-	(4.0)	-	(4.0)	-	100.00%
2	Sun Pharma Global Inc.	USD	62.50	49,138.9	165,783.5	214,923.0	0.6	-	-	(2.9)	-	(2.9)	-	100.00%
3	Sun Pharmaceutical (Bangladesh) Ltd.	BDT	0.80	48.0	525.1	1,028.0	454.9	-	1,036.0	265.5	96.5	169.0	-	72.50%
4	Sun Pharmaceutical Industries, Inc. (Previously Known as Caraco Pharmaceutical Laboratories Ltd)	USD	62.50	13,595.8	(8,412.5)	53,662.1	48,478.8	1,790.3	43,229.9	(1,998.3)	(761.6)	(1,236.7)	-	100.00%
5	Sun Farmaceutica Do Brasil Ltda (Previously Known as TKS Farmaceutica Ltda)	BRL	19.34	107.8	(1,763.6)	506.8	2,162.6	-	404.2	(416.2)	-	(416.2)	-	100.00%
6	Sun Pharma De Mexico S.A. DE C.V.	MXN	4.07	4.1	517.5	837.6	316.0	-	1,189.1	278.9	86.1	192.8	-	75.00%
7	SPII De Mexico S.A. DE C.V.	MXN	4.07	0.2	-	0.2	-	-	-	-	-	-	-	100.00%
8	Sun Pharmaceutical Peru S.A.C	PEN	20.27	0.0	(96.3)	1.0	97.3	-	-	(27.0)	-	(27.0)	-	99.33%
9	OOO "Sun Pharmaceutical Industries" Ltd.	RUB	1.07	0.1	(81.5)	420.9	502.3	-	527.7	(54.0)	(4.1)	(49.9)	-	99.00%
10	Sun Pharma de Venezuela, CA	VEF	9.94	0.5	(1,002.3)	238.8	1,240.6	-	-	(443.7)	-	(443.7)	-	100.00%
11	Chattem Chemicals Inc.	USD	62.50	2,152.1	1,312.4	3,678.4	213.9	-	1,826.0	268.2	104.4	163.8	-	100.00%
12	Taro Development Corporation	USD	62.50	0.0	(0.4)	1,241.3	1,241.7	-	-	-	-	-	-	100.00%
13	Alkaloida Chemical Company Zrt.	USD	62.50	16,759.4	18,549.6	45,132.2	9,823.2	160.9	799.1	(1,201.3)	-	(1,201.3)	-	99.99%
14	Sun Pharmaceutical UK Ltd.	GBP	92.44	0.1	(84.4)	475.6	559.9	-	597.2	22.5	0.0	22.5	-	100.00%
15	Sun Pharmaceutical Industries (Australia) Pty. Ltd.	AUD	47.53	0.0	(95.7)	50.6	146.3	-	184.7	(52.4)	-	(52.4)	-	100.00%
16	Aditya Acquisition Company Ltd.	ILS	15.74	-	(8.2)	35.0	43.2	-	166.8	(5.4)	3.0	(8.4)	-	100.00%
17	Sun Pharmaceutical Industries (Europe) B.V.	EURO	67.20	1.2	(147.6)	395.8	542.2	-	711.7	22.2	-	22.2	-	100.00%
18	Sun Pharmaceuticals Italia S.R.L.	EURO	67.20	0.7	(296.8)	511.2	807.3	-	494.3	9.5	3.7	5.8	-	100.00%
19	Sun Pharmaceutical Spain, S.L.U	EURO	67.20	0.2	(257.6)	129.2	386.6	-	125.7	(27.1)	-	(27.1)	-	100.00%
20	Sun Pharmaceuticals Germany GmbH	EURO	67.20	1.7	(188.0)	191.9	378.2	-	494.9	8.7	-	8.7	-	100.00%
21	Sun Pharmaceuticals France	EURO	67.20	2.5	(16.7)	190.3	204.5	-	367.3	0.3	-	0.3	-	100.00%
22	Sun Pharma Global (FZE)	USD	62.50	257.8	81,592.6	83,093.6	1,243.2	1,815.4	22,106.3	11,325.6	-	11,325.6	-	100.00%
23	Sun Pharmaceuticals (SA) (Pty) Ltd.	ZAR	5.12	0.0	(0.1)	-	0.1	-	-	(0.0)	-	(0.0)	-	100.00%
24	Sun Global Canada Pty. Ltd.	USD	62.50	0.1	(1.0)	-	0.9	-	-	(0.0)	-	(0.0)	-	100.00%
25	Sun Laboratories FZE	USD	62.50	765.8	(2.7)	763.1	(0.0)	-	-	(0.8)	-	(0.8)	-	100.00%
26	Sun Global Development FZE	USD	62.50	178.7	(2.6)	195.7	19.6	-	-	(0.8)	-	(0.8)	-	100.00%
27	Sun Pharma Japan Ltd.	JPY	0.52	82.2	(289.2)	14.1	221.1	-	-	(87.0)	0.2	(87.2)	-	100.00%
28	Sun Pharma Philippines Inc	PHP	1.40	12.1	(183.2)	280.1	451.2	-	134.0	(88.7)	-	(88.7)	-	100.00%
29	Sun Pharma MEA JLT	USD	62.50	170.2	73.6	244.3	0.5	-	-	(24.9)	-	(24.9)	-	100.00%
30	Sun Pharma Health Care FZE	USD	62.50	178.7	(6.4)	172.3	(0.0)	-	-	(11.5)	-	(11.5)	-	100.00%
31	Sun Pharmaceuticals Korea Ltd.	KRW	0.06	6.0	(1.1)	6.1	1.2	-	-	(0.1)	-	(0.1)	-	100.00%
32	Caraco Pharmaceuticals Pvt. Ltd.	INR	1.00	0.1	(0.2)	0.0	0.1	-	-	(0.0)	-	(0.0)	-	100.00%
33	Sun Pharma Laboratories Limited	INR	1.00	400.5	185,706.6	192,910.9	6,803.8	21,762.6	43,725.7	1,807.2	2,034.2	(227.0)	-	100.00%
34	Morley and Company Inc	USD	62.50	0.2	(0.1)	0.2	0.1	-	-	-	-	-	-	100.00%
35	Taro Pharmaceutical Industries Ltd. (TARO)	USD	62.50	16,445.3	71,787.1	91,742.3	3,509.9	-	23,609.4	32,037.6	1,771.6	30,266.0	-	68.87%
36	Taro Pharmaceuticals Inc.	CAD	49.03	14.5	40,716.4	43,364.3	2,633.4	-	19,284.6	15,882.8	3,836.8	12,046.0	-	68.87%
37	Taro Pharmaceuticals U.S.A. Inc.	USD	62.50	526.5	(1,325.4)	43,084.0	43,882.9	209.3	48,107.4	1,816.7	662.1	1,154.6	-	68.87%
38	Taro Pharmaceuticals North America, Inc.	USD	62.50	219.5	15,530.4	16,281.7	531.8	-	5,169.5	3,073.6	-	3,073.6	-	68.87%
39	Taro Pharmaceuticals Europe B.V.	EURO	67.20	1.2	(29.1)	3.8	31.7	-	-	(2.2)	-	(2.2)	-	68.87%
40	Taro Pharmaceuticals Ireland Ltd.	EURO	67.20	134.5	(350.4)	79.9	295.8	-	-	(86.3)	-	(86.3)	-	68.87%
41	Taro International Ltd.	USD	62.50	0.0	2.9	255.2	252.3	-	397.0	(13.8)	(0.0)	(13.8)	-	68.87%
42	Taro Pharmaceuticals UK Ltd.	GBP	92.44	0.0	(681.1)	241.9	923.0	-	728.8	(99.9)	0.2	(100.1)	-	68.87%

₹ in Million

Sr No	Name of the Subsidiary Company	Reporting Currency	Part 'A': Subsidiaries										Proposed Dividend	% of shareholding	
			Rate	Capital	Reserve	Total Assets	Total Liabilities	Investment other than Investment in Subsidiary	Turnover	Profit/ (Loss) before Taxation	Profit/ (Loss) after Taxation				
43	Taro Hungary Intellectual Property Licensing LLC.	USD	62.50	6,355.9	2.4	6,361.6	3.3	-	-	-	46.9	4.7	42.2	40.8	68.87%
44	Taro Pharmaceuticals Canada Ltd.	CAD	49.03	-	(0.0)	0.0	(0.0)	-	-	-	(0.0)	-	(0.0)	-	68.87%
45	Taro Pharmaceutical India Private Ltd.	INR	1.00	0.1	0.7	0.8	-	-	-	-	(0.2)	-	(0.2)	-	68.87%
46	Aditya Pharma Private limited	USD	62.50	0.2	(0.1)	-	(0.1)	-	-	-	(0.0)	-	(0.0)	-	100.00%
47	Alkaloïda Sweden AB	SEK	7.24	0.4	-	6.8	6.4	-	6.7	25.6	(25.6)	-	(25.6)	-	100.00%
48	Dusa Pharmaceuticals Inc	USD	62.50	0.6	1,142.1	12,040.8	10,898.1	-	6,898.3	2,198.5	826.8	1,371.7	-	-	100.00%
49	URL Pharma Inc	USD	62.50	4,416.9	1,070.3	5,487.3	0.1	-	-	-	-	-	-	-	100.00%
50	AR Scientific Inc	USD	62.50	(83.8)	10.3	(72.7)	0.8	-	0.0	(0.1)	-	(0.1)	-	-	100.00%
51	Mutual Pharmaceutical Company, Inc.	USD	62.50	5,086.0	6,743.1	13,860.3	2,031.2	-	6,051.3	(50.9)	73.0	(123.9)	-	-	100.00%
52	United Research Laboratories, Ltd.	USD	62.50	415.4	(91.9)	338.3	14.8	-	9.9	(96.9)	(37.4)	(59.5)	-	-	100.00%
53	Dungan Mutual Associates, LLC	USD	62.50	(77.1)	29.1	(37.8)	10.2	-	-	23.6	9.2	14.4	-	-	100.00%
54	URL PharmPro, LLC	USD	62.50	(350.9)	(286.6)	(707.1)	(69.6)	-	-	(177.9)	(69.1)	(108.8)	-	-	100.00%
55	Dusa Pharmaceuticals New York Inc	USD	62.50	-	(121.7)	(117.4)	4.3	-	-	(46.8)	-	(46.8)	-	-	100.00%
56	FastStone Mercantile Company Private Limited	INR	1.00	0.1	9.0	9.1	0.0	9.1	-	(0.0)	0.0	(0.0)	-	-	100.00%
57	Neetnav Real Estate Private Limited	INR	1.00	3.0	11.0	3,222.0	3,208.0	3,051.5	0.8	2.8	1.0	1.8	-	-	100.00%
58	Realstone Multitrade Private Limited	INR	1.00	0.1	9.0	9.1	0.0	9.1	-	(0.0)	0.0	(0.0)	-	-	100.00%
59	Skisen Labs Private Limited	INR	1.00	0.1	(9.2)	364.9	374.0	8.9	(0.0)	(18.1)	0.0	(18.1)	-	-	100.00%
60	Softdeal Trading Company Private Limited	INR	1.00	0.1	8.6	8.7	0.0	8.7	-	(0.0)	0.0	(0.0)	-	-	100.00%
61	Universal Enterprises (Pvt) Ltd.	INR	1.00	4.5	0.8	5.3	0.0	-	-	(0.0)	-	(0.0)	-	-	100.00%
62	Sun Pharma Switzerland Ltd.	CHF	64.28	6.4	(0.9)	5.8	0.3	-	-	(0.5)	-	(0.5)	-	-	100.00%
63	Sun Pharma Holdings (Previously Known as Nograd Holdings)	USD	62.50	213,799.6	350.2	214,153.4	3.6	-	173.2	170.3	-	170.3	-	-	100.00%
64	Silverstreet Developers LLP	INR	1.00	0.5	2,775.7	2,776.2	0.0	2,775.6	-	(0.2)	(0.0)	(0.2)	-	-	100.00%
65	Pharmaluce Inc.	USD	62.50	5,459.3	(195.8)	5,984.4	720.9	-	1,143.7	(310.6)	(114.8)	(195.8)	-	-	100.00%
66	PI Real Estate Ventures LLC	USD	62.50	562.6	58.5	1,804.8	1,183.7	-	-	92.9	34.4	58.5	-	-	100.00%
67	Sun Pharma East Africa Limited	KS	0.66	0.1	(0.6)	6.3	6.8	-	-	(0.9)	(0.3)	(0.6)	-	-	100.00%
68	Ranbaxy Drugs Limited	INR	1.00	31.0	1,699.2	1,756.7	26.5	1,725.0	-	30.5	0.4	30.1	-	-	100.00%
69	Vidyut Investments Limited	INR	1.00	250.1	(226.5)	24.7	1.1	-	-	2.0	0.8	1.2	-	-	100.00%
70	Gulfic Pharma Limited	INR	1.00	0.5	3.5	4.0	-	2.8	-	0.2	-	0.2	-	-	100.00%
71	Basics GmbH,	EURO	67.20	327.6	180.8	2,970.4	2,462.0	-	1,557.7	(10.8)	-	(10.8)	-	-	100.00%
72	Ranbaxy GmbH	EURO	67.20	1.7	-	294.8	293.1	-	111.8	-	-	-	-	-	100.00%
73	Ranbaxy Pharmaceuticals Ukraine LLC	UAH	2.70	107.7	3.7	225.6	114.2	-	514.0	6.6	10.3	(3.7)	-	-	100.00%
74	Ranbaxy Morocco LLC,	MAD	6.29	77.0	(234.6)	486.1	643.7	-	316.5	(153.1)	1.6	(154.7)	-	-	100.00%
75	Ranbaxy-PRP (Peru) S.A.C.,	PEN	20.27	88.0	(173.1)	46.5	131.6	-	14.0	(61.6)	-	(61.6)	-	-	100.00%
76	Ranbaxy Holdings (U.K.) Ltd.,	GBP	92.44	2,824.6	129.8	2,961.6	7.2	-	-	0.2	-	0.2	-	-	100.00%
77	Ranbaxy Pharmacie Genériques SAS,	EURO	67.20	1,676.5	(3,009.2)	692.0	2,024.7	-	1,706.8	(429.7)	-	(429.7)	-	-	100.00%
78	Office Pharmaceutique Industriel Et Hospitalier,SARL ("OPIH SARL ")	EURO	67.20	89.4	(29.6)	233.2	173.4	-	350.1	0.9	-	0.9	-	-	100.00%
79	Ranbaxy Italia S.P.A	EURO	67.20	13.4	(11.5)	929.8	927.9	-	1,345.4	(29.7)	-	(29.7)	-	-	100.00%
80	Ranbaxy Belgium NV,	EURO	67.20	37.8	(0.5)	53.8	16.5	-	-	-	-	-	-	-	100.00%
81	Ranbaxy Pharmaceuticals (Pty) Ltd. (Previously known as Be-Tab's Pharmaceuticals (Proprietary) Ltd.)	ZAR	5.12	-	91.3	2,204.7	2,113.4	-	1,327.1	(262.4)	-	(262.4)	-	-	100.00%
82	Sonke Pharmaceuticals (Pty) Ltd,	ZAR	5.12	-	(27.0)	583.1	610.1	-	134.1	(62.5)	(17.4)	(45.1)	-	-	70.00%
83	Ranbaxy South Africa Proprietary Ltd.	ZAR	5.12	1.9	459.6	1,510.6	1,049.1	-	1,052.3	(65.2)	18.8	(84.0)	-	-	100.00%
84	Ranbaxy Egypt (L.L.C.)	EGP	8.19	39.7	138.2	715.2	537.3	-	376.2	35.4	11.8	23.6	-	-	100.00%
85	Rexcel Egypt (L.L.C.),	EGP	8.19	2.0	(7.4)	64.5	69.9	-	21.7	(5.8)	0.1	(5.9)	-	-	100.00%
86	Ranbaxy (UK) Limited	GBP	92.44	2,010.6	(1,058.4)	2,212.5	1,260.3	-	2,672.7	295.8	21.1	274.7	-	-	100.00%

Sr No	Name of the Subsidiary Company	Reporting Currency	Rate	Capital	Reserve	Total Assets	Total Liabilities	Investment other than Investment in Subsidiary	Turnover	Profit / (Loss) before Taxation		Proposed Dividend	% of shareholding
										Profit / (Loss) before Taxation	Provision for Taxation		
87	Ranbaxy Poland S.P.Z.o.o.,	PLN	16.50	70.8	60.4	179.5	48.3	-	717.4	31.6	7.7	59.2	100.00%
88	Ranbaxy Nigeria Ltd.,	NGN	0.32	12.7	934.9	2,157.4	1,209.8	-	1,054.4	115.5	53.1	62.4	85.31%
89	Ranbaxy (Thailand) Co., Limited	THB	1.92	31.7	33.0	140.5	75.8	-	262.4	44.4	9.0	35.4	100.00%
90	Ohm Laboratories Inc.,	USD	62.50	14.9	5,277.8	17,913.2	12,620.5	-	17,134.5	(484.1)	(152.1)	(332.0)	100.00%
91	Ranbaxy Laboratories Inc.,	USD	62.50	-	6,105.9	21,252.7	15,146.8	-	12,999.2	5,499.1	1,923.6	3,575.5	100.00%
92	Ranbaxy Signature LLC,	USD	62.50	-	(555.8)	27.3	583.1	-	195.3	111.0	-	111.0	67.50%
93	Ranbaxy Pharmaceutical, Inc.,	USD	62.50	-	6,138.1	32,275.9	26,137.8	-	20,309.0	(197.2)	(41.9)	(155.3)	100.00%
94	Ranbaxy, Inc.,	USD	62.50	812.5	14,057.0	36,624.4	21,754.9	-	1,873.9	(69.4)	39.9	(109.3)	100.00%
95	Ranbaxy USA, Inc,	USD	62.50	9,871.7	(75.3)	10,740.6	944.2	-	-	(0.0)	(1.9)	1.9	100.00%
96	Ranbaxy Ireland Ltd.,	EURO	67.20	477.9	732.9	1,745.1	534.3	-	3,099.2	212.9	24.9	188.0	100.00%
97	ZAO Ranbaxy,	RUB	1.07	3.2	424.6	2,334.5	1,906.7	-	3,157.2	(44.4)	(3.8)	(40.6)	100.00%
98	Laboratórios Ranbaxy, S.L.,	EURO	67.20	67.2	(87.2)	518.6	538.6	-	592.0	80.8	-	80.8	100.00%
99	Ranbaxy Malaysia Sdn. Bhd.,	MYR	16.86	134.9	533.8	1,799.6	1,130.9	-	1,144.4	(301.7)	(7.6)	(294.1)	71.22%
100	Ranbaxy Farmaceutica Ltda.,	BRL	19.34	335.9	(970.1)	1,132.7	1,766.9	-	1,113.5	(411.0)	-	(411.0)	100.00%
101	Ranbaxy Europe Ltd.,	GBP	92.44	0.9	153.7	281.7	127.1	-	515.0	24.5	6.9	17.6	100.00%
102	Ranbaxy Australia Proprietary Ltd.,	AUD	47.53	437.3	(1,305.0)	514.0	1,381.7	-	1,671.9	41.2	-	41.2	100.00%
103	Ranbaxy Pharmaceuticals Canada Inc.,	CAD	49.02	110.3	209.0	1,528.9	1,209.6	-	2,356.7	(282.1)	26.0	(308.1)	100.00%
104	S.C Terapia S.A.,	RON	15.20	380.3	6,797.7	12,152.6	4,974.6	-	8,064.4	1,449.9	228.1	1,221.8	96.70%
105	Be- Tabs Investments (Proprietary) Ltd.,	ZAR	5.12	-	18.2	20.7	2.5	-	-	(0.1)	-	(0.1)	100.00%
106	Ranbaxy Portugal - Com E Desenvolv/DeProd Farmaceuticos Unipessoal Lda	EURO	67.20	0.3	(0.6)	0.7	1.0	-	-	(0.5)	-	(0.5)	100.00%
107	Ranbaxy (Netherlands) BV.	USD	62.50	36,784.3	12,981.0	50,155.8	390.5	103.6	-	(4,306.5)	3.1	(4,309.6)	100.00%

## Note :

- 0.0\* represents amount less than 0.05 million and rounded off.
- The above does not include 3 Skyline LLC, Tarochem Drive LLC, Tarochem Ltd, Orta Ltd, Sirius Laboratories Inc, Taro Pharmaceutical Laboratories Inc being subsidiaries of Taro Pharmaceutical Industries Ltd, Sun Universal Ltd., Caraco Pharma Inc. and Khyati Realty ME Ltd. as they have no operation and does not have any Assets, Liabilities or Equity as on the close of their Financial Year.
- With effect from January 1, 2015 Sun Pharma Global Inc. merged with the Holding company.
- With effect from March 1, 2015 Sun Pharma MEA JLT merged with Sun Pharma Global FZE.
- With effect from October 28, 2014 Ranbaxy USA, Inc. has been liquidated.
- With effect from February 28, 2015 Aditya Pharma Private Limited has been liquidated.
- With effect from December 10, 2014 and December 11, 2014 Orta Limited and Tarochem Limited has been dissolved respectively.
- With effect from May 6, 2014 Sun Universal Ltd. and Khyati Realty ME Ltd. has been dissolved.

**Part “B”: Associate Companies and Joint Ventures**

Sr. No	Name of Associates/Joint Ventures	Jointly Controlled Entity			Associate			₹ in Million
		Artes Biotechnology GmbH	MSD - Sun LLC	S & I Ophthalmic LLC	Zenotech Laboratories Limited	Daiichi Sankyo (Thailand) Limited	Reanal Limited	
1.	Latest audited Balance Sheet Date	31-Dec-14	31-Mar-15	31-Mar-15	31-Mar-15	31-Mar-15	NA	31-Mar-15
2.	Shares of Associate/Joint Ventures held by the company on the year end							
	No.	15,853	NA	2,828,257	890,874	3,441	1,16,667	9,340,000
	Amount of Investment in Associates/Joint Venture	192.1	753.2	312.5	2,463.5	161.0	280.0	934.0
	Extend of Holding %	45.00%	50.00%	50.00%	46.84%	26.90%	23.35%	24.91%
3.	Description of how there is significant influence	NA	NA	NA	NA	NA	NA	NA
4.	Reason why the associate/joint venture is not consolidated	NA	NA	NA	NA	Refer note 51(a)	Refer note 51(b)	Refer note 51(c)
5.	Net worth attributable to Shareholding as per latest audited Balance Sheet	58.8	(408.6)	(189.5)	(272.6)	1,259.5	NA	NA
6.	Profit / (Loss) for the year							
	i. Considered in Consolidation	(15.20)	(493.80)	(94.8)	(143.2)	17.6	NA	NA
	ii. Not Considered in Consolidation	(18.60)	(493.80)	(94.8)	(160.9)	65.5	NA	NA

For and on behalf of the Board

DILIP S. SHANGHVI  
 Managing Director

SUDHIR V. VALIA  
 Wholetime Director

SAILESH T. DESAI  
 Wholetime Director

UDAY V. BALDOTA  
 Chief Financial Officer  
 Mumbai, 11th August, 2015

SUNIL R. AJMERA  
 Company Secretary